docetaxel anhydrous has been researched along with pf-06463922 in 2 studies
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (pf-06463922) | Trials (pf-06463922) | Recent Studies (post-2010) (pf-06463922) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 229 | 27 | 224 |
Protein | Taxonomy | docetaxel anhydrous (IC50) | pf-06463922 (IC50) |
---|---|---|---|
Sodium-dependent phosphate transport protein 2B | Homo sapiens (human) | 0.0002 | |
HLA class II histocompatibility antigen gamma chain | Homo sapiens (human) | 0.0002 | |
High affinity nerve growth factor receptor | Homo sapiens (human) | 0.024 | |
Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | 0.006 | |
Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | 0.0003 | |
Tyrosine-protein kinase Fer | Homo sapiens (human) | 0.0033 | |
Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0027 | |
Tyrosine-protein kinase FRK | Homo sapiens (human) | 0.053 | |
Focal adhesion kinase 1 | Homo sapiens (human) | 0.017 | |
Activated CDC42 kinase 1 | Homo sapiens (human) | 0.017 | |
Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.014 | |
NT-3 growth factor receptor | Homo sapiens (human) | 0.046 | |
Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0186 | |
ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0177 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L | 1 |
Albuquerque de Almeida, F; Cooper, M; Iadeluca, L; InĂªs, M; Smith, S | 1 |
1 review(s) available for docetaxel anhydrous and pf-06463922
Article | Year |
---|---|
Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lactams, Macrocyclic; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors | 2023 |
1 other study(ies) available for docetaxel anhydrous and pf-06463922
Article | Year |
---|---|
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |